AXSOME THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
AXSOME THERAPEUTICS, INC. (AXSM) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 8.08 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 8.78M shares, a 7.51% decline year-over-year.
- AXSOME THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 9.49M shares, a 7.08% decline year-over-year.
- AXSOME THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 10.21M shares, a 14.80% increase year-over-year.
- AXSOME THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 8.89M shares, a 28.87% increase year-over-year.
- AXSOME THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 8.76M shares, a 7.64% decline from fiscal 2024.
- AXSOME THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 9.49M shares, a 0.93% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 9.40M shares, a 27.84% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.35M shares, a 35.39% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 8.08M shares 10-Q · filed 2026-08-10 | |||||
| 2026-03-31 | 8.78M shares 10-Q · filed 2026-05-04 | |||||
| 2025-12-31 | 8.76M shares 10-K · filed 2026-02-23 | |||||
| 2025-09-30 | 9.31M shares 10-Q · filed 2025-11-03 | |||||
| 2025-06-30 | 9.85M shares 10-Q · filed 2026-08-10 | |||||
| 2025-03-31 | 9.49M shares 10-Q · filed 2026-05-04 | |||||
| 2024-12-31 | 9.49M shares 10-K · filed 2026-02-23 | |||||
| 2024-09-30 | 9.50M shares 10-Q · filed 2025-11-03 | |||||
| 2024-06-30 | 9.98M shares 10-Q · filed 2025-08-04 | |||||
| 2024-03-31 | 10.21M shares 10-Q · filed 2025-05-05 | |||||
| 2023-12-31 | 9.40M shares 10-K · filed 2026-02-23 | |||||
| 2023-09-30 | 9.03M shares 10-Q · filed 2024-11-12 | |||||
| 2023-06-30 | 8.79M shares 10-Q · filed 2024-08-05 | |||||
| 2023-03-31 | 8.89M shares 10-Q · filed 2024-05-06 | |||||
| 2022-12-31 | 7.35M shares 10-K · filed 2025-02-18 | |||||
| 2022-09-30 | 7.28M shares 10-Q · filed 2023-11-06 | |||||
| 2022-06-30 | 7.29M shares 10-Q · filed 2023-08-07 | |||||
| 2022-03-31 | 6.90M shares 10-Q · filed 2023-05-09 | |||||
| 2021-12-31 | 5.43M shares 10-K · filed 2024-02-23 | |||||
| 2021-09-30 | 4.91M shares 10-Q · filed 2022-11-07 | |||||
| 2021-06-30 | 4.79M shares 10-Q · filed 2022-08-09 | |||||
| 2021-03-31 | 4.71M shares 10-Q · filed 2022-05-02 | |||||
| 2020-12-31 | 3.89M shares 10-K · filed 2023-02-28 | |||||
| 2020-09-30 | 4.08M shares 10-Q · filed 2021-11-08 | |||||
| 2020-06-30 | 4.17M shares 10-Q · filed 2021-08-09 | |||||
| 2020-03-31 | 4.18M shares 10-Q · filed 2021-05-10 | |||||
| 2019-12-31 | 3.53M shares 10-K · filed 2022-03-01 | |||||
| 2019-09-30 | 3.30M shares 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | 3.27M shares 10-Q · filed 2020-08-10 | 3.27M shares 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | 3.28M shares 10-Q · filed 2020-05-11 | |||||
| 2018-12-31 | 2.41M shares 10-K · filed 2021-03-01 | |||||
| 2018-09-30 | 4.83M shares 10-Q · filed 2019-11-07 | |||||
| 2018-06-30 | 5.01M shares 10-Q · filed 2019-08-08 | |||||
| 2018-03-31 | 4.86M shares 10-Q · filed 2019-05-09 | |||||
| 2017-12-31 | 4.41M shares 10-K · filed 2020-03-12 | 4.41M shares 10-K · filed 2018-03-07 | ||||
| 2017-09-30 | 2.56M shares 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | 2.42M shares 10-Q · filed 2018-08-08 | 2.42M shares 10-Q · filed 2017-08-09 | ||||
| 2017-03-31 | 2.44M shares 10-Q · filed 2018-05-08 | |||||
| 2016-12-31 | 2.11M shares 10-K · filed 2019-03-15 | 2.11M shares 10-K · filed 2017-03-07 | ||||
| 2016-09-30 | 2.05M shares 10-Q · filed 2017-11-08 | |||||
| 2016-06-30 | 2.03M shares 10-Q · filed 2017-08-09 | |||||
| 2016-03-31 | 1.27M shares 10-Q · filed 2017-05-09 | |||||
| 2015-12-31 | 1.27M shares 10-K · filed 2018-03-07 | |||||
| 2015-09-30 | 3.58M shares 10-Q · filed 2016-11-14 | |||||
| 2015-06-30 | 3.46M shares 10-Q · filed 2016-08-09 | |||||
| 2015-03-31 | 2.05M shares 10-Q/A · filed 2016-08-09 | |||||
| 2014-12-31 | 1.98M shares 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |